文章：

可切除非小细胞肺癌的新辅助与辅助免疫治疗

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

原文发布日期：23 April 2024

DOI: 10.3390/cancers16091619

类型: Article

开放获取: 是

英文摘要：

Non-small cell lung cancer, even when diagnosed in early stages, has been linked with poor survival rates and distant recurrence patterns. Novel therapeutic approaches harnessing the immune system have been implemented in early stages, following the designated steps of advanced NSCLC treatment strategies. Immune-checkpoint inhibitor (ICI) regimens as monotherapy, combinational, or alongside chemotherapy have been intensely investigated as adjuvant, neoadjuvant, and, more recently, perioperative therapeutic strategies, representing pivotal milestones in the evolution of early lung cancer management while holding great potential for the future. The subject of current ongoing research is optimizing treatment outcomes for patient subsets with different needs and identifying biomarkers that could be predictive of response while translating the trials’ endpoints to survival rates. The aim of this review is to discuss all current treatment options with the pros and cons of each, persistent challenges, and future perspectives on immunotherapy as illuminating the path to a new era for resectable NSCLC.

摘要翻译： 

非小细胞肺癌即使在早期诊断阶段，仍与较低的生存率和较高的远处复发风险相关。借鉴晚期非小细胞肺癌的治疗策略，早期阶段已开始应用基于免疫系统的新型治疗方法。免疫检查点抑制剂方案——无论是单药治疗、联合治疗还是与化疗联用——已作为辅助治疗、新辅助治疗以及近年兴起的围手术期治疗策略被深入研究，这些进展标志着早期肺癌治疗演进的关键里程碑，并为未来治疗带来巨大潜力。当前研究重点在于优化不同需求患者亚群的治疗效果，寻找可预测治疗反应的生物标志物，并将临床试验终点转化为实际生存获益。本综述旨在系统探讨现有治疗方案的优劣、当前面临的持续挑战以及免疫治疗的未来前景，为可切除非小细胞肺癌开启新时代的治疗路径提供指引。

原文链接：

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC